Corpus Intelligence IC Memo — FULLER MEMORIAL HOSPITAL 2026-04-26 10:40 UTC
IC Memo — FULLER MEMORIAL HOSPITAL
Investment Committee Memorandum | MA | 109 beds | Grade C | EBITDA uplift $3.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

FULLER MEMORIAL HOSPITAL

CCN 224021 | BRISTOL, MA | 109 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

FULLER MEMORIAL HOSPITAL is a 109-bed suburban community hospital in BRISTOL, MA with $41.4M in net patient revenue and a 21.2% operating margin. The hospital serves a payer mix of 16.3% Medicare, 6.9% Medicaid, and 76.9% commercial.

Thesis: Turnaround. Our ML models identify $3.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 21.2% to 28.5% (+736bps).

Net Revenue HCRIS$41.4M
Current EBITDA COMPUTED$8.8M
Operating Margin COMPUTED21.2%
Occupancy HCRIS85.9%
Revenue / Bed COMPUTED$380K
Net-to-Gross HCRIS69.0%
Distress Probability ML45.6%

2. Market Context & Competitive Position

99
MA Hospitals
-12.2%
State Median Margin
56
Comparable Hospitals

MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of 21.2% places it above the state median. Among 56 size-comparable peers (54-218 beds), the median margin is -10.7%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (54-218), prioritizing same-state peers. 56 hospitals in the comp set.

HospitalStateBedsRevenueMargin
FULLER MEMORIAL HOSPITAL (Target)MA109$41.4M21.2%
NEWTON WELLESLEY HOSPITALMA216$624.3M-4.7%
BETH ISRAEL DEACONESS - PLYMOUMA150$349.1M2.6%
MOUNT AUBURN HOSPITALMA186$337.4M-8.4%
STEWARD ST. ANNES HOSPITALMA175$322.3M12.8%
FAULKNER HOSPITALMA147$316.6M-7.9%
EMERSON HOSPITALMA111$315.1M-10.1%
WINCHESTER HOSPITALMA178$314.9M-3.9%
BROCKTON HOSPITAL INC.MA175$305.2M-18.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$869K+210bp18mo
Cost to Collect4.5%2.5%$828K+200bp12mo
Denial Rate Reduction12.0%6.5%$820K+198bp12mo
A/R Days Reduction5200.0%3800.0%$504K+122bp9mo
Clean Claim Rate88.0%96.0%$26K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$869K
Cost to Collect
$828K
Denial Rate Reduction
$820K
A/R Days Reduction
$504K
Clean Claim Rate
$26K
Total EBITDA Uplift$3.0M
Current EBITDA$8.8M
+ RCM Uplift+$3.0M
Pro Forma EBITDA$11.8M
Current Margin21.2%
Pro Forma Margin28.5%
WC Released (1x)$1.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$13.5M$88.2M6.55x45.6%
Base (11x exit)10.0x11.0x$13.5M$101.4M7.53x49.7%
Bull Case9.0x11.0x$12.1M$115.9M9.56x57.0%
Bull (12x exit)9.0x12.0x$12.1M$130.0M10.72x60.7%
Bear Case11.0x10.0x$14.8M$68.6M4.63x35.9%
Bear (11x exit)11.0x11.0x$14.8M$80.3M5.42x40.2%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 56 hospitals with 54-218 beds
  • Same-state prioritization (n=57)
  • Comp margins: P25=-18.2% / P50=-10.7% / P75=-0.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.